In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies

The molecular target for the classical complement pathway (CP) is defined by surface-bound immunoglobulins. Therefore, numerous anticancer monoclonal antibodies (mAbs) exploit the CP as their effector mechanism. Conversely, the alternative complement pathway (AP) is spontaneously induced on the host...

Full description

Bibliographic Details
Main Authors: Aleksandra Urban, Alan Majeranowski, Grzegorz Stasiłojć, Patrycja Koszałka, Anna Felberg, Michał Taszner, Jan M. Zaucha, Marcin Okrój
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
complement system
CLL
NHL
rituximab
obinutuzumab
Online Access:https://www.mdpi.com/2072-6694/14/5/1270

Internet

https://www.mdpi.com/2072-6694/14/5/1270

Similar Items